Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children

Dwarfism, Pituitary Clinical Trial

Status Recruiting

Clinical Trial Summary

This study evaluates the safety and efficiency of Pegylated Somatropin (PEG Somatropin) Injection in the treatment of endogenous growth hormone deficiency (GHD) in the broad population of children. Half of participants will receive the high dose, while the other half will receive the low dose.

Clinical Trial Description

n/a

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Dwarfism, Pituitary

Clinical Trial Details

NCT number	NCT02314676
Study type	Interventional
Source	GeneScience Pharmaceuticals Co., Ltd.
Contact	Junfen Fu, Ph.D
Phone	13777457849
Email	fjf68@qq.com
Status	Recruiting
Phase	Phase 4
Start date	November 2014

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01187550` - Predictive Markers in Chinese Growth Hormone Deficiency (GHD) Children Treated With Saizen®	Phase 4
Completed	`NCT00102258` - Role of Nutrition and Hormones in Boys With Disordered Growth	Phase 2
Completed	`NCT00097513` - National Cooperative Growth Study (NCGS) of Optimal Nutropin AQ and Nutropin Dosing in Pubertal Growth Hormone-Deficient (GHD) Patients	Phase 4
Completed	`NCT00097526` - Bone Mineral Density (BMD) in Adolescents With Growth Hormone Deficiency (GHD)	Phase 4